Status:
UNKNOWN
Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients
Lead Sponsor:
Taejoon Pharmaceutical Co., Ltd.
Conditions:
Dry Eye Syndromes
Eligibility:
All Genders
20+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is a prospective randomized study compared with active control and placebo arms.
Eligibility Criteria
Inclusion
- Male or female, age 20 or over
- Patient who have been diagnosed with dry eye syndrome at least 6 months ago
- Screening both eyes, the corrected visual acuity is 0.2 or more
- Written informed consent to participate in the trial
Exclusion
- Screening visits within 2 months the patients with systemic or ocular disorders affected the test results (ocular surgery, trauma, or disease)
- Intraocular pressure(IOP)\> 21 mmHg
Key Trial Info
Start Date :
October 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT05346783
Start Date
October 14 2021
End Date
June 1 2023
Last Update
April 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hyung Keun, Lee
Seoul, South Korea